141 related articles for article (PubMed ID: 15124044)
1. Recent advances in therapy for gastric cancer.
Yeh KH; Cheng AL
J Formos Med Assoc; 2004 Mar; 103(3):171-85. PubMed ID: 15124044
[TBL] [Abstract][Full Text] [Related]
2. Advances in the therapy of gastric cancer.
Macdonald JS
Gastric Cancer; 2002; 5 Suppl 1():35-40. PubMed ID: 12772886
[TBL] [Abstract][Full Text] [Related]
3. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
6. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
8. Can adjuvant chemoradiotherapy replace extended lymph node dissection in gastric cancer?
Jansen EP; Boot H; van de Velde CJ; van Sandick J; Cats A; Verheij M
Recent Results Cancer Res; 2012; 196():229-40. PubMed ID: 23129378
[TBL] [Abstract][Full Text] [Related]
9. Resection for gastric cancer in the community.
van de Velde CJ
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S90-3. PubMed ID: 16399441
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
[TBL] [Abstract][Full Text] [Related]
11. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
12. Current status and future perspectives in gastric cancer management.
Roukos DH
Cancer Treat Rev; 2000 Aug; 26(4):243-55. PubMed ID: 10913380
[TBL] [Abstract][Full Text] [Related]
13. Role of post-operative chemoradiation in resected gastric cancer.
Macdonald JS
J Surg Oncol; 2005 Jun; 90(3):166-70. PubMed ID: 15895449
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
Weese JL; Harbison SP; Stiller GD; Henry DH; Fisher SA
Surgery; 2000 Oct; 128(4):564-71. PubMed ID: 11015089
[TBL] [Abstract][Full Text] [Related]
17. Treatment of localized gastric cancer.
Macdonald JS
Semin Oncol; 2004 Aug; 31(4):566-73. PubMed ID: 15297947
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Yeh KH; Lu YS; Hsu CH; Lin JF; Hsu C; Kuo SH; Li SJ; Cheng AL
Oncology; 2005; 69(1):88-95. PubMed ID: 16088236
[TBL] [Abstract][Full Text] [Related]
19. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer.
Shen YC; Li CP; Yen CJ; Hsu C; Lin YL; Lin ZZ; Chen LT; Su WC; Chao Y; Yeh KH; Cheng AL
Oncology; 2014; 87(2):104-13. PubMed ID: 25011938
[TBL] [Abstract][Full Text] [Related]
20. Selecting the best treatment for an individual patient.
Bittoni A; Faloppi L; Giampieri R; Cascinu S
Recent Results Cancer Res; 2012; 196():307-18. PubMed ID: 23129382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
